Skip to Main Content

Active Surveillance of the Small Renal Mass

Conditions

Kidney

What is the purpose of this trial?

Primary Objectives/Endpoints:

  • Tumor growth rate in maximal dimension between CRG gene status, wild-type (M0) vs. mutant (M1) groups

Secondary Objectives/Endpoints:

  • To determine if established clear cell mRNA subtypes (A and B) are predictive of tumor growth rate or need for surgical intervention
  • To determine the association between CRG status surgical intervention (analysis by threshold and/or patient preference) between M0 and M1 groups To investigate if HIF2 or Ki-67 protein expression assessed by Automated Quantitative Analysis of immunohistochemistry are predictors of rapid tumor growth Comparison of Patient Anxiety Scores over time and correlation to tumor growth Determination of MRI imaging characteristics dynamic contrast enhancement and apparent diffusion coefficients are predictive of rapid tumor growth
  • Trial with
    Yale University School of Medicine
  • Start Date
    07/27/2014
  • End Date
    07/31/2021
Trial Image

For more information about this study, contact:

Neta Shanwetter Levit

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/02/2020
  • Study HIC
    #1312013110